154 related articles for article (PubMed ID: 32114514)
21. Molecular genetic aberrations of ovarian and uterine carcinosarcomas--a CGH and FISH study.
Schipf A; Mayr D; Kirchner T; Diebold J
Virchows Arch; 2008 Mar; 452(3):259-68. PubMed ID: 18193277
[TBL] [Abstract][Full Text] [Related]
22. Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression.
Ashley CW; Da Cruz Paula A; Kumar R; Mandelker D; Pei X; Riaz N; Reis-Filho JS; Weigelt B
Gynecol Oncol; 2019 Jan; 152(1):11-19. PubMed ID: 30415991
[TBL] [Abstract][Full Text] [Related]
23. Novel targeted therapies in ovarian and uterine carcinosarcomas.
Han C; Altwerger G; Menderes G; Haines K; Feinberg J; Lopez S; Manzano A; Varughese J; Santin AD
Discov Med; 2018 Jun; 25(140):309-319. PubMed ID: 30021104
[TBL] [Abstract][Full Text] [Related]
24. In-depth molecular profiling of the biphasic components of uterine carcinosarcomas.
McConechy MK; Hoang LN; Chui MH; Senz J; Yang W; Rozenberg N; Mackenzie R; McAlpine JN; Huntsman DG; Clarke BA; Gilks CB; Lee CH
J Pathol Clin Res; 2015 Jul; 1(3):173-85. PubMed ID: 27499902
[TBL] [Abstract][Full Text] [Related]
25. [Carcinosarcomas of the uterus: molecular-genetic and morphological features].
Levitskaia NV; Pozharisskiĭ KM; Vostriukhina OA; Alekseeva LN; Nemtsova MV; Matrosova IV; Kharitonova TV; Poddubnaia IV
Arkh Patol; 2012; 74(1):7-11. PubMed ID: 22712296
[TBL] [Abstract][Full Text] [Related]
26. The High Mobility Group A1 (HMGA1) gene is highly overexpressed in human uterine serous carcinomas and carcinosarcomas and drives Matrix Metalloproteinase-2 (MMP-2) in a subset of tumors.
Hillion J; Roy S; Heydarian M; Cope L; Xian L; Koo M; Luo LZ; Kellyn K; Ronnett BM; Huso T; Armstrong D; Reddy K; Huso DL; Resar LMS
Gynecol Oncol; 2016 Jun; 141(3):580-587. PubMed ID: 27001612
[TBL] [Abstract][Full Text] [Related]
27. Defective DNA mismatch repair and XRCC2 mutation in uterine carcinosarcomas.
Taylor NP; Gibb RK; Powell MA; Mutch DG; Huettner PC; Goodfellow PJ
Gynecol Oncol; 2006 Jan; 100(1):107-10. PubMed ID: 16169065
[TBL] [Abstract][Full Text] [Related]
28. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets.
Cimbaluk D; Rotmensch J; Scudiere J; Gown A; Bitterman P
Gynecol Oncol; 2007 Apr; 105(1):138-44. PubMed ID: 17175012
[TBL] [Abstract][Full Text] [Related]
29. Mutational and Immunophenotypic Profiling of a Series of 8 Tubo-ovarian Carcinosarcomas Revealed a Monoclonal Origin of the Disease.
Trento M; Munari G; Carraro V; Lanza C; Salmaso R; Pizzi S; Santoro L; Chiarelli S; Dal Santo L; Nardelli GB; Saccardi C; Nicoletto O; Baldoni A; Rugge M; Fassan M
Int J Gynecol Pathol; 2020 Jul; 39(4):305-312. PubMed ID: 31688243
[TBL] [Abstract][Full Text] [Related]
30. Cutaneous basal cell carcinosarcomas: evidence of clonality and recurrent chromosomal losses.
Harms PW; Fullen DR; Patel RM; Chang D; Shalin SC; Ma L; Wood B; Beer TW; Siddiqui J; Carskadon S; Wang M; Palanisamy N; Fisher GJ; Andea A
Hum Pathol; 2015 May; 46(5):690-7. PubMed ID: 25704628
[TBL] [Abstract][Full Text] [Related]
31. Localization of the VEGF and angiopoietin genes in uterine carcinosarcoma.
Emoto M; Charnock-Jones DS; Licence DR; Ishiguro M; Kawai M; Yanaihara A; Saito T; Hachisuga T; Iwasaki H; Kawarabayashi T; Smith SK
Gynecol Oncol; 2004 Dec; 95(3):474-82. PubMed ID: 15581949
[TBL] [Abstract][Full Text] [Related]
32. Molecular alterations of PIK3CA in uterine carcinosarcoma, clear cell, and serous tumors.
Bashir S; Jiang G; Joshi A; Miller C; Matrai C; Yemelyanova A; Caputo TA; Holcomb KM; Ellenson LH; Gupta D
Int J Gynecol Cancer; 2014 Sep; 24(7):1262-7. PubMed ID: 25078343
[TBL] [Abstract][Full Text] [Related]
33. Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma.
Mahdi H; Xiu J; Reddy SK; DeBernardo R
J Surg Oncol; 2015 Aug; 112(2):188-94. PubMed ID: 26250968
[TBL] [Abstract][Full Text] [Related]
34. HER-2/neu oncogene in uterine carcinosarcoma on tamoxifen therapy.
Raspollini MR; Mecacci F; Paglierani M; Marchionni M; Taddei GL
Pathol Res Pract; 2005; 201(2):141-4. PubMed ID: 15901136
[TBL] [Abstract][Full Text] [Related]
35. Survival and risk factors associated with uterine sarcomas and carcinosarcomas in stage I and II.
Visnovsky J; Kudela E; Slavik P; Krkoska M; Buocik P; Szepe P; Danko J
Neuro Endocrinol Lett; 2015; 36(8):750-7. PubMed ID: 26921575
[TBL] [Abstract][Full Text] [Related]
36. ERBB-2 gene overexpression and amplification in uterine sarcomas.
Amant F; Vloeberghs V; Woestenborghs H; Debiec-Rychter M; Verbist L; Moerman P; Vergote I
Gynecol Oncol; 2004 Dec; 95(3):583-7. PubMed ID: 15581967
[TBL] [Abstract][Full Text] [Related]
37. Targeted Genomic Profiling Reveals Recurrent KRAS Mutations in Mesonephric-like Adenocarcinomas of the Female Genital Tract.
Mirkovic J; McFarland M; Garcia E; Sholl LM; Lindeman N; MacConaill L; Dong F; Hirsch M; Nucci MR; Quick CM; Crum CP; McCluggage WG; Howitt BE
Am J Surg Pathol; 2018 Feb; 42(2):227-233. PubMed ID: 28984674
[TBL] [Abstract][Full Text] [Related]
38. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma.
Livasy CA; Reading FC; Moore DT; Boggess JF; Lininger RA
Gynecol Oncol; 2006 Jan; 100(1):101-6. PubMed ID: 16157366
[TBL] [Abstract][Full Text] [Related]
39. Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition.
Cuevas IC; Sahoo SS; Kumar A; Zhang H; Westcott J; Aguilar M; Cortez JD; Sullivan SA; Xing C; Hayes DN; Brekken RA; Bae-Jump VL; Castrillon DH
Proc Natl Acad Sci U S A; 2019 Dec; 116(51):25880-25890. PubMed ID: 31772025
[TBL] [Abstract][Full Text] [Related]
40. Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?
McCluggage WG
J Clin Pathol; 2002 May; 55(5):321-5. PubMed ID: 11986333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
